Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

m schizophrenia.

Indiplon Update

The Company met with the FDA in July for an end of review meeting related to the December 12, 2007 approvable letter for indiplon capsules. The FDA meeting focused on the three additional requirements outlined in the approvable letter. After exchange of correspondence regarding meeting minutes, the Company continues to await the FDA's final version of these minutes to determine the next course of action related to indiplon capsules.

Conference Call and Webcast Today at 5:00 PM Eastern Time

Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 1-800-895-0198 (US) or 785-424-1053 (International) using the conference ID: 7NEURO. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-388-9074 (US) or 402-220-1117 (International) using the conference ID: 7NEURO. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's web
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Dallas-based TopMD™ Skin Care today announced results of ... of their flagship product, CLn® BodyWash for ... in the May/June 2013 issue of Pediatric Dermatology ... Cleanser Shows Clinical Response and Excellent Acceptability in the ... consistent use of the product by 18 pediatric patients ...
(Date:5/21/2013)... Dimensional Insight, a developer of business intelligence ... Health System, a 275-bed hospital based in Cumberland, ... help it analyze its data more quickly. Western Maryland ... through Dimensional Insight’s recently announced partnership with Premier ... has massive amounts of data in disparate systems, such ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Romio ... people with trusted services & businesses, announced today that ... Emergency Medical Care. , Emergency Medical Care is located ... services 24 hours a day. The guarantee of ... is a promising resource for the neighborhood and a ...
(Date:5/21/2013)... Reporter , , MONDAY, May 20 (HealthDay News) -- Young ... a higher risk of getting into car crashes, but ... missed sleep on weekends puts them in even greater ... is another challenge to adolescents that comes with lack ... founder of the Center for Injury Research and Prevention ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Racial disparities exist ... hospitals in the United States, according to a large ... undergo surgery as part of their initial treatment, researchers ... whites to have surgery in the early stages of ... for stage 1 and stage 2 disease than white ...
Breaking Medicine News(10 mins):Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... NY) For the third time in four months, the ... National Institutes of Health (NIH) has awarded Albert Einstein College ... helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken ... latest awardee Neel Gandhi, M.D. , assistant professor ...
... July 27, 2010 Researchers at UT Southwestern Medical ... doses of corticosteroids given repeatedly over several weeks may ... affects more than 1 million people in the U.S. ... sometimes use illegally to bulk up muscle, corticosteroids are ...
... By Madonna Behen HealthDay Reporter , MONDAY, July ... Administration has required that all epilepsy drugs bear a warning ... doctors report that only certain medications may increase the risk ... the findings and say the paper raises more questions than ...
... such as everolimus that target the protein mTOR are used ... respond to the treatment. A team of researchers, led by ... has now identified a way to help predict which patients ... that human cancer cells with mutations in the PIK3CA gene ...
... major research company affiliated with the University of Colorado ... the University of Colorado,s Anschutz Medical Campus to more ... laboratory to the patient. CPC, formally known as the ... Incorporated building across the street from the campus on ...
... Society for Radiation Oncology (ASTRO) has named N. Reed ... diagnostic radiology, as its 2010 Honorary Member, which is ... researchers and leaders in disciplines other than radiation oncology, ... with this honor during the Awards Ceremony at ASTRO,s ...
Cached Medicine News:Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Researchers uncover biological rationale for why intensive lupus treatment works 2Health News:Researchers uncover biological rationale for why intensive lupus treatment works 3Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 2Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 3Health News:University of Colorado joins forces with major research affiliate 2Health News:ASTRO names radiologist, ABR president Society's 2010 Honorary Member 2
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
... Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today ... that once-daily Victoza ® in combination with metformin produced sustained and significantly ... ® plus metformin at 52 weeks. , ... Key findings from the study include: , ...
... JACKSONVILLE, Fla. , June 28 ... of its SurgiSteer™ laparoscopic instruments.  Developed from licensed ... will exploit single port laparoscopic surgery with its ... and Endo Scissors, available in both free and ...
Cached Medicine Technology:New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 2New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 3New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 4New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 5New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 6New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 7Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments 2
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: